A Novel Multiplex Immunoassay for the Early Detection of Bladder Cancer
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Bladder Cancer
- 发起方
- Cedars-Sinai Medical Center
- 入组人数
- 173
- 试验地点
- 2
- 主要终点
- 1. To assess the ability to recruit and retain an appropriate high-risk group of subjects into a 4-year longitudinal study monitoring them for the development of bladder cancer.
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.
详细描述
Environmental exposures, specifically tobacco smoke, increases the risk of many cancers, including bladder cancer. To date, there are no diagnostics capable of detecting bladder cancer early, that is prior to clinical presentation. Because of this severe limitation, nearly 30% of patients initially present with stage 2 and higher bladder cancer. Stage 2 bladder cancer has a 5-year survival of 50%, while stage 3/4 have a 5-year survival of \<20%. Ideally, bladder cancer would be preventable. Unfortunate, this has not come to fruition. If these stage 2-4 bladder cancer cases could be detected at Stage 1 (5-yr survival \>94%), then its possible to see an improvement in bladder cancer survival rates (21-23). in this study, a urine-based diagnostic that possesses the potential to accurately identify patients who harbor bladder cancer prior to clinical manifestation will be tested.
研究者
Charles Rosser
Professor
Cedars-Sinai Medical Center
入排标准
入选标准
- •Participants must be:
- •Age 50 years or older
- •\>20 pack year history of tobacco exposure
- •Free of any malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
- •Scheduled to be evaluated in the Pulmonary Rehab Clinic or Lung Cancer Screening Clinic
- •Willing and able to give written informed consent
- •Willing to provide voided urine sample
- •Be able and willing to complete semi-annual research clinic visits for 4 years
排除标准
- •Participants must not have:
- •History of hematuria (microscopic or gross) within 2 years of signing consent.
- •Previous history of bladder cancer
- •A known active urinary tract infection or urinary retention
- •An active stone disease (renal or bladder) or renal insufficiency (creatinine \>2.0 mg/dL) - Serum creatinine value can be up to 2 years before consent, otherwise repeat.
- •An ureteral stents, nephrostomy tubes or bowel interposition
- •A recent genitourinary instrumentation (within 7 days prior to collection of voided urine sample)
结局指标
主要结局
1. To assess the ability to recruit and retain an appropriate high-risk group of subjects into a 4-year longitudinal study monitoring them for the development of bladder cancer.
时间窗: 5 years
Ability to recruit
2. To report the sensitivity and specificity of the multiplex immunoassay ability to detect bladder cancer in patients with high risk of developing bladder cancer: >50 years and >40 pack year history of tobacco exposure.
时间窗: 5 years
Performance of multiplex test in this study
3. To develop a prediction risk calculator from this cohort using cutting edge machine learning techniques (e.g., random forest) incorporating biomarker data and clinical data.
时间窗: 5 years
Development of a risk calculator